Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Period	dileps
2014-12-31	N/A
2015-12-31	N/A
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	-$24.84
2021-12-31	-$16.68
2022-12-31	-$8.28
2023-12-31	-$0.37

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$61.76	+1.91%	1.21M
3
4
5

Oruka Therapeutics Inc. (ORKA) Earnings Per Share (EPS)

EPS (Earnings Per Share) Data

Get Oruka Therapeutics Inc. Data in Excel

More ORKA Financial Data